Ann: MedAdvisor June 2020 Quarterly Activities Report, page-3

  1. 1 Posts.
    +1. Not bad indeed. Look at % revenue growth... demonstrates (local market) revenue generation doing well.

    • Q4 FY20 Operating Revenue (up 31.4% from Q4 FY19) & (up 40.8% from Q3 FY20)
    • Q4 FY20 Total Revenue (up 41.0% v Q4 FY19) & (up 99.8% vs Q3 FY20)
    • FY20 Operating Revenue (up 17.0% from FY19)
    • FY20 Total Revenue (up 20.8% from FY19)

    Operating Costs Q4 FY20 $1.095m improved from Q3 FY20 $2.668m from better cost management, granted yes, a significant amount of it is boosted by government grants and incentives. This is operating steadily but agree... would love to see international revenues start contributing for this to fly. $MDR reporting Asia being on track to deliver revenue next quarter is promising. Keep watching.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
8.0¢
Change
0.001(1.27%)
Mkt cap ! $50.02M
Open High Low Value Volume
8.0¢ 8.0¢ 7.9¢ $44.53K 558.3K

Buyers (Bids)

No. Vol. Price($)
1 12658 7.9¢
 

Sellers (Offers)

Price($) Vol. No.
8.0¢ 84920 2
View Market Depth
Last trade - 14.07pm 25/07/2025 (20 minute delay) ?
MDR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.